Psychoactive fungi

Psyched Wellness Initiates Study on AME-1 Extract for Gut Health

Retrieved on: 
Tuesday, March 30, 2021
Fungi, Organisms, Branches of biology, Psychoactive fungi, Entheogens, Amanita muscaria, Non-timber forest products, Amanita, Mushroom, Dietary supplement

Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods.

Key Points: 
  • Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods.
  • The Company's objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category.
  • The Company is in the process of developing a line of Amanita Muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.
  • This news release includes data that has been obtained from third party sources, including the findings from the Toxicology Assessment.

Psirenity granted approval to conduct Jamaica’s first psilocybin clinical trial to help manage depression

Retrieved on: 
Monday, March 29, 2021
Entheogens, Psychoactive drugs, Mycotoxins, Organophosphates, Psilocybin, Psychoactive fungi

TORONTO, March 29, 2021 (GLOBE NEWSWIRE) -- Psirenity, a wholly owned subsidiary of New Leaf Canada Inc., today announced it has received approval to conduct the first clinical trial protocol with psilocybin in Jamaica.

Key Points: 
  • TORONTO, March 29, 2021 (GLOBE NEWSWIRE) -- Psirenity, a wholly owned subsidiary of New Leaf Canada Inc., today announced it has received approval to conduct the first clinical trial protocol with psilocybin in Jamaica.
  • The trial is aimed at assessing the safety, tolerability and pharmacokinetics of two unique psilocybin micro-dose products developed by the Psirenity team in the management of mild to moderate depression.
  • The clinical trial is not only a historical first for Jamaica, it showcases the advanced state of Psirenity and its commitment to science-backed methods for improving wellness.
  • We are confident our Phase 1 trial will highlight the medical benefits and positive impacts of using our innovative psilocybin delivery systems to manage depression in adults, says Psirenity CEO Chris McCullough.

New Wave Subsidiary, Way of Will Inc., Announces Launch of Functional Mushroom Capsules and Functional Mushroom Powder as Part of New Emerging Mushroom Collection

Retrieved on: 
Thursday, March 25, 2021
Fungi, Non-timber forest products, Entheogens, Psychoactive fungi, Basidiomycota, Edible fungi, Mushroom, Psychedelic drug, Organisms

Further to the announcement, the company is releasing the Functional Mushroom Powder and the Functional Mushroom Capsules from the collection to the U.S. market.

Key Points: 
  • Further to the announcement, the company is releasing the Functional Mushroom Powder and the Functional Mushroom Capsules from the collection to the U.S. market.
  • Paving the way to a larger collection of specialty mushroom products, the mushroom powder and capsules will be the first step in Way of Will's journey into the psychedelics space.
  • The product launch, featuring a house blend of five functional mushrooms and fungi available in both capsule and powder format, aim to naturally boost immunity.
  • They are loaded with vitamins, nutrients, and antioxidants that support a healthy immune system.

Pure Extracts Orders First Shipment of Functional Mushrooms for e-Commerce Store

Retrieved on: 
Tuesday, March 16, 2021
Fungi, Non-timber forest products, Basidiomycota, Edible fungi, Mushroom, Pure, Organisms, Entheogens, Psychoactive fungi

VANCOUVER, British Columbia, March 16, 2021 (GLOBE NEWSWIRE) -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (Pure Extracts or the Company), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, is pleased to announce that its wholly owned subsidiary, Pure Mushrooms Corp. (Pure Mushrooms), has ordered its first shipment of functional mushrooms from its British Columbia co-packer.

Key Points: 
  • VANCOUVER, British Columbia, March 16, 2021 (GLOBE NEWSWIRE) -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (Pure Extracts or the Company), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, is pleased to announce that its wholly owned subsidiary, Pure Mushrooms Corp. (Pure Mushrooms), has ordered its first shipment of functional mushrooms from its British Columbia co-packer.
  • Pure Mushrooms has developed three premium, functional mushroom formulations, that come in safe and convenient vegan capsules.
  • Pure Extracts CEO, Ben Nikolaevsky, remarked, We are excited to be ordering the first Pure Mushrooms products to launch our direct-to-consumer, online store.
  • About Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ)
    Pure Extracts features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia.

Minerco Acquires $2.5M of Revenue from White Label CBD Company, WLCCO Inc

Retrieved on: 
Sunday, March 14, 2021
Psychoactive fungi, Entheogens

Minerco completes purchase of WLCCO Inc and increases psilocybin production capacity

Key Points: 
  • Oakland, California--(Newsfile Corp. - March 14, 2021) - Minerco (OTC Pink: MINE) announced today that they have acquired WLCCO Inc, a white label CBD company that generates approximately $2.5 million in annual revenue.
  • This strategic purchase includes crucial equipment, increasing microdosed psilocybin tablet production capacity by 1 million units daily.
  • In markets where psilocybin is not legal, Minerco will manufacture unleaded medical mushrooms including Chaga and Lion Mane as legal alternatives.
  • With the acquisition of WLCCO, Minerco leadership can now say that they have achieved three out of the four goals laid at the Summit with the acquisition of WLCCO.

Optimi Health Accelerates Psilocybin Clinical Trial Program with IMPACT

Retrieved on: 
Tuesday, March 9, 2021
Psychoactive fungi, Entheogens, Shrooms

Optimi instituted a program in 2020 to identify and engage with a suitable partner in its quest to become one of the first companies to utilize natural psilocybin mushrooms as a primary component for product formulization and requisite clinical trial efforts.

Key Points: 
  • Optimi instituted a program in 2020 to identify and engage with a suitable partner in its quest to become one of the first companies to utilize natural psilocybin mushrooms as a primary component for product formulization and requisite clinical trial efforts.
  • Optimis JJ Wilson, (Board Chair), notes, In order to use naturally harvested psilocybin mushrooms for a clinical trial, the psilocybin must first be grown in a GMP grade facility.
  • The IMPACT program provides Optimi expert clinical support towards commercializing proposed psilocybin-based formulations through the conduct of clinical trials and expert assistance towards securing regulatory approval.
  • On Behalf of the Board of Directors, Optimi Health Corp.
    Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets.

Pure Extracts and ShroomBloom Sign Psychedelic Mushroom Supply Letter of Intent

Retrieved on: 
Tuesday, March 9, 2021
Entheogens, Psychoactive fungi, Fungi, Organisms, Psilocybe

VANCOUVER, British Columbia, March 09, 2021 (GLOBE NEWSWIRE) -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (Pure Extracts or the Company), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, is pleased to announce that it has signed a Letter of Intent (LOI) with ShroomBloom Labs/Floja Bioscience Inc. (ShroomBloom) to enter into an agreement for the supply of psychedelic mushroom biomass.

Key Points: 
  • VANCOUVER, British Columbia, March 09, 2021 (GLOBE NEWSWIRE) -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (Pure Extracts or the Company), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, is pleased to announce that it has signed a Letter of Intent (LOI) with ShroomBloom Labs/Floja Bioscience Inc. (ShroomBloom) to enter into an agreement for the supply of psychedelic mushroom biomass.
  • ShroomBloom is a British Columbia based mushroom cultivator whose unique growing method uses a sustainable forest product to grow organic Psilocybe Azurescens mushrooms.
  • ShroomBloom is currently conducting a bio-tech research and development program utilizing artificial intelligence (AI) to industrialize the cultivation of psychedelic mushrooms.
  • The LOI is subject to both ShroomBloom and Pure Extracts holding Dealer's Licences under the Controlled Drugs and Substances Act (CDSA).

ATMA Journey Centers Announces International Expansion to Costa Rica, Providing Clients a Range of Psychedelic Treatments Including Ayahuasca

Retrieved on: 
Monday, March 8, 2021
Entheogens, Health sciences, Hallucinations, Psychoactive drugs, Psychoactive fungi, Drug discovery, Branches of biology, Psilocybin, Hallucinogen, Psychedelic drug, Therapy

ATMA Azul will provide an immersive experience in which clients will be able to experience a range of healing and transformational modalities as part of multi-day experiences, ceremonies, and retreats.

Key Points: 
  • ATMA Azul will provide an immersive experience in which clients will be able to experience a range of healing and transformational modalities as part of multi-day experiences, ceremonies, and retreats.
  • ATMA Azul will incorporate a comprehensive protocol that emphasizes safety and security of clients, providing clients full-service week-long programs that include well-appointed accommodations, holistic and organic food prepared by certified chefs, and leading-edge psychedelic medicine therapy and protocols.
  • Our goal is to provide a relief to this pressure, and to assist clients in healing and reconnecting with themselves."
  • ATMA was the first private company in Canada to conduct legal psychedelic-assisted therapy with psilocybin, one of the active hallucinogens found in 'magic mushrooms'.

Successful Medical Applications of Psilocybin Help Erode Harmful Stigmas

Retrieved on: 
Thursday, March 4, 2021
Entheogens, Psychoactive fungi, Psychoactive drugs, Psilocybin, Shrooms

Among the popular fields of study for biotech companies are gene editing, tissue engineering and regeneration, nanobiotechnology and others.

Key Points: 
  • Among the popular fields of study for biotech companies are gene editing, tissue engineering and regeneration, nanobiotechnology and others.
  • Pure Extracts plans to sell functional mushroom wellness products through its newly incorporated, wholly owned subsidiary, Pure Mushrooms Corp.
  • Sales will take place direct-to-consumer through an e-Commerce portal that the Company is establishing, and the brand will be called 'Pure Mushrooms'.
  • "Clinical trials continue to show that psilocybin therapies may provide tremendous help with these conditions, that we see every day in our clinics.

Successful Medical Applications of Psilocybin Help Erode Harmful Stigmas

Retrieved on: 
Thursday, March 4, 2021
Entheogens, Psychoactive fungi, Psychoactive drugs, Psilocybin, Shrooms

Among the popular fields of study for biotech companies are gene editing, tissue engineering and regeneration, nanobiotechnology and others.

Key Points: 
  • Among the popular fields of study for biotech companies are gene editing, tissue engineering and regeneration, nanobiotechnology and others.
  • Pure Extracts plans to sell functional mushroom wellness products through its newly incorporated, wholly owned subsidiary, Pure Mushrooms Corp.
  • Sales will take place direct-to-consumer through an e-Commerce portal that the Company is establishing, and the brand will be called 'Pure Mushrooms'.
  • "Clinical trials continue to show that psilocybin therapies may provide tremendous help with these conditions, that we see every day in our clinics.